Fig. 1
Fig. 2
Fig. 3
Disease and biofunctions identified by IPA ordered with respect to activation z-score
| Diseases or functions annotation | P-value | Activation z-score | Number of molecules |
|---|---|---|---|
| Inflammation of joints | 4.61E−09 | −3.228* | 143 |
| Inflammatory response | 1.71E−06 | −2.003* | 103 |
| Activation of leukocytes | 6.71E−07 | −1.664 | 88 |
| Inflammation of respiratory system component | 6.93E−06 | −1.518 | 76 |
| Inflammation of body cavity | 4.07E−06 | −1.467 | 139 |
| Rheumatoid arthritis | 2.18E−07 | −1.387 | 102 |
| Inflammation of lungs | 3.60E−06 | −1.379 | 54 |
| Allergic pulmonary eosinophilia | 2.95E−06 | −1.342 | 12 |
| Inflammation of organs | 1.03E−07 | −1.088 | 187 |
| Inflammation of absolute anatomical region | 6.76E−06 | −1.049 | 153 |
| Immune response of tumour cell lines | 1.06E−05 | −0,788 | 29 |
| Dermatitis | 9.31E−06 | −0.363 | 68 |
Primers and TaqMan probes used in this study for BIV and GAPDH gene amplification
| Primer/Probe | Sequence 5′ → 3′ | Position in target sequence | Product length (bp) | Application |
|---|---|---|---|---|
| BIVg723F | GAAGCAGACATCGAATCAGA | 723–742a | 552 | BIV standard |
| BIVg1274R | TCTTTTGTGGTTTCTGGAGC | 1255–1274 a | DNA | |
| BTG1F | TGATGCTGGTGCTGAGTATGTG | 4–25b | 182 | GAPDH standard |
| BTG2R | CCTTCAAGTGAGCCTGCAGCAA | 164–185 b | DNA | |
| BIVg1074F | ACAAGCCACCCTGATCTCAGTA | 1074–1095 a | 128 | RT-qPCR and |
| BIVg1202R | TCCTTGGGTTCCCTGATGAATGT | 1181–1202 a | qPCR- | |
| BIVg1107P | Cy5 - AACTTTCAGACAGTGGGTGCTGCAGG - BHQ3 | 1107–1132 a | - | BIV gag gene |
| BTG3F | CCACTGGGGTCTTCACTACCAT | 33–54 b | ||
| BTG4R | AAGTTAATTGCACCCGGGCTCT | 137–158 b | 126 | GAPDH qPCR- |
| BTG5P | JOE - CTGGAGAGGAGGGTGTAACAGGA - BHQ1 | 83–105 b | - |
The top-scoring regulatory networks identified using IPA software
| Consistency score | Node total | Regulator total | Regulators | Target total | Target molecules in dataset | Diseases & functions |
|---|---|---|---|---|---|---|
| 1.291 | 20 | 4 | ELF4, INSIG1, INSR, mir-148 | 15 | ACSL1, C1QA, CA2, CD68, CXCL2, DUSP1, FABP4, FDFT1, GABRB3, HSPD1, LDLR, LGALS1, MMP9, PRDM1, VCAM1 | Inflammation of joints |
| −7.211 | 15 | 1 | INSR | 13 | ALDH2, CLCA1, DUSP1,EGR1, FABP4,GADD45A, HSPD1, LGALS1, MFN2, MMP9, PRDM1, SERPINB1, VCAM1 | Inflammatory response |
| −7.500 | 6 | 1 | RABGEF1 | 4 | CTSH, GBA, HEXB, LDLR | Metabolism of protein |
| −7.506 | 5 | 1 | ALDH1A2 | 3 | ALDH1A3, CCN2, CD44 | Neonatal death |
| −8.660 | 5 | 1 | DDX3X | 3 | CCND1, ODC1, RPS5 | Metabolism of protein |
Comparison of gene expression changes observed in microarray analysis and RT-qPCR
| Gene | Reference sequence ID | Primer sequence (5′–3′) | FC | |
|---|---|---|---|---|
| Microarray | RT-qPCR | |||
| UCHL5* | 174481* NM_ | F: ACAAAGACAACTTGCTGAGGAACCC | N/A | N/A |
| R: GGCAACCTCTGACTGAATAGCACTT | ||||
| ATR | XM_002685057.2 | F: AATGCACGTGTCCTTCGATA | 2.45 | 1.05 |
| R: TGAAAAGGCCAAGACTCATGT | ||||
| LTA | NM_001013401.2 | F: CCCTCAGAGCCTCGCTTT | 2.00 | 1.19 |
| R: GCGAGACATCAGAAGAAAGAGC | ||||
| IL-18 | NM_001562 | F: AGACAGGTTGATTTCCCTGGT | −1.50 | −1.15 |
| R: CCTGGAATCAGATCACTTTGG | ||||
| HYAL2 | XM_024982390 | F: GCGACCAGAGGGGGAACTC | −1.50 | −1.03 |
| R: TAGCACTGGCAGCGAAAGTGCA | ||||
| F: TGGTGGAGACTGCCTGCG | ||||
| DCTN6 | XM_024986251 | R: CCGACTAAAGAGGTTCTAGCAC | 3.00 | 1.12 |